Statins clinical applications

The action of HDACs transcriptional repression pathways is not an academic issue, since HDAC inhibitors have long been known to be very potent cytostatic and differentiating agents. Thus, for example, a number of cell lines of cancerous origin can be driven to cease proliferation via the application of such HDAC inhibitors as tricho-statin A or sodium butyrate. In addition, oncoproteins that are produced as a result of chromosomal translocations in leukemias are known to depend on HDAC targeting for action compounds that force a release of HDAC from these chimeric proteins are successfiilly used in clinical practice to treat certain forms of leukemia. 

---